Tempus has built the world’s largest library of clinical & molecular data and an operating system to make that data accessible and useful, starting with cancer.

Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, [5] for oncology, cardiology, radiology, and depression. The company went public …

1 day ago · Tempus plans to report its complete fourth quarter and full year 2025 financial results during its earnings call in February 2026. About Tempus Tempus is a technology company …

May 31, 2025 · Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.

1 day ago · Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.

Tempus AI ’s (TEM) preliminary results show its total contract value (TCV) surpassed $1.1 billion, marking the highest level in its history. The update reflects how quickly the AI‑driven …

1 day ago · Tempus AI TEM stock has delivered a remarkable 105% gain over the past year, driven by strong performance across both its Genomics and Data segments, surpassing initial …

TEMPUS® is a technology company that has built the world's largest library of clinical and molecular data and an operating system to make that information accessible and useful for …

Launched in the United States in 2015, Tempus is now one of the largest sequencers of cancer patients in the world. Having built its platform for oncology, it has expanded to …

Jun 6, 2024 · Tempus doesn’t directly treat patients but instead provides a platform for healthcare providers and researchers. This platform acts as a central hub, collecting and analyzing vast …